We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

A malaria vaccine candidate is to enter human safety trials following animal studies that showed it protects against all strains of the malaria parasite.

UK scientists recently identified a single mechanism that the malaria parasite relies on to enter human red blood cells, according to BBC News.

"It revealed what we think is the parasite's Achilles heel in the way it invades our cells and provided a target for potential new vaccines," said co-author of the study Gavin Wright, from the Wellcome Trust Sanger Institute.

Now, a team at Oxford University, United Kingdom, has harnessed this knowledge to design the new vaccine candidate, which proved successful in animal studies.

"We have found a way of making antibodies that kill all different strains of malaria parasites," Sandy Douglas from the University of Oxford told BBC News. "This is still early phase research in animals. The next step is to do clinical trials in people."

If the vaccine proves safe in humans, it could enter clinical trials within the next two to three years, said the Oxford team.

Early results from clinical trials of a vaccine candidate, RTS,S/AS01, in Africa show that it protects about half of people vaccinated from malaria. But scientists say that a more effective vaccine is needed.

Link to full article in BBC News